The major aim of pharmacovigilance systems is early detection of known or unknown drug safety problems, detection of increases in frequency, identification of risk factors quantifying risks, preventing patients from being affected unnecessarily.
Of all the steps, ascertaining the safety of drugs is the most crucial step off all, preventing more harm from the drug to the body than the disease itself. So, it becomes most important for CCL to identify the safety information about the drug in a timely manner to avoid any future uncertainty. CCL takes a comprehensive and rigorous approach to pharmacovigilance activities. We are dedicated to establishing, maintaining, and communicating quality safety information throughout the life-cycle of our products. Since patient safety is our number one priority, it is important that we share our approach to pharmacovigilance and our commitment to patient safety.
Our pharmacovigilance experts are medical professionals with extensive safety and/or clinical and healthcare experience who are trained in medication safety, pharmacovigilance and worldwide medicinal product regulations. These experienced professionals continually monitor product compliance under regulatory law across the nation.
Our mission is “Enabling Healthy and happy lives by providing quality healthcare solutions globally”. Our commitment towards pharmacovigilance is to optimize the safe use of CCL Products through continuous evaluation of benefits and risks of our products life cycle with the implementation of risk management strategies combined with our robust safety governance framework.
CCL collects and analyze safety data throughout a product’s life cycle. In case of any adverse affect reported by a healthcare practitioner or patient, the adverse event reports are continuously added to our database. They help contribute to the overall understanding of the safety profits of our products.
DRAP PHARMACOVIGILANCE GUIDELINES
In case you come across any adverse events related to our products, please feel free to connect with CCL’s Pharmacovigilance (PV) team.
Phone: +92 42 111 225 678
mail.pv@cclpharma.com